gomiliximab
mAbexperimental
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00046488)
Timeline
Indications
Mechanism of action
- Immunoglobulin epsilon Fc receptorANTAGONIST
FCER2 antagonist
This mAb has been shown to block IgE synthesis in human B cells.
- Immunoglobulin epsilon Fc receptorINHIBITOR
FCER2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLumiliximab ↗
- ChEMBLCHEMBL2109151 ↗
Also known as
- gomiliximab
- idec-152
- idec-152
- idec-152
- lumiliximab
- lumiliximab
- lumiliximab
- monoclonal antibody lumiliximab
- p5e8 si-3401 gomiliximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00801060 | Phase 2 | Feb 1, 2008 | Biogen |
| NCT00391066 | Phase 2 | Nov 1, 2006 | Biogen |
| NCT00103558 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2004 | Biogen |
| NCT00058396 | Phase 1 | Oct 1, 2002 | Cornell University, National Cancer Institute (NCI) |
| NCT00046488 | Phase 1 | Sep 1, 2002 | Biogen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 4 | 4 | 2 | 2002 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2002 |
3 organizations
Page 1 / 1